WASHINGTON, D.C. – Phyllis Arthur, Executive Vice President and Head of Health Policy and Programs of the Biotechnology Innovation Organization (BIO) released the following statement on the December 2025 ACIP meeting.
“For decades, the CDC’s Advisory Committee on Immunization Practices (ACIP) has been a shining example of America’s leadership in scientific excellence and evidence-based decision-making.
This year we’ve seen this once-transparent, apolitical process led by clinicians and infectious disease experts eroded meeting by meeting.
Adopting recommendations without rigorous analysis leaves American children and families vulnerable to deadly infectious diseases that have long been preventable because of vaccines. It sows confusion among patients and providers and undermines access.
Today’s decision to change the recommendation for hepatitis B vaccination for newborns, despite 35 years of progress toward eliminating the disease in children, will result in increased rates of hepatitis B, causing liver disease and cancer.
BIO urges ACIP to reaffirm its long-standing, transparent, balanced, evidence-based processes that support timely vaccine access and safeguard the nation’s ability to prevent deadly infectious diseases.”
###
About the Biotechnology Innovation Organization (BIO)
BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org.